Journal Mobile Options
Table of Contents
Vol. 21, No. 5, 2014
Issue release date: June 2014
Section title: Original Paper
Neuroimmunomodulation 2014;21:250-256
(DOI:10.1159/000357309)

Evaluation of Neuroimmunomodulatory Activity of Recombinant Human Interferon α

Mehta S. · Mukherjee S. · Balasubramanian D. · Chowdhary A.
Department of Virology and Immunology, Haffkine Institute, Mumbai, India

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 10/3/2013 10:04:04 AM
Accepted: 11/15/2013
Published online: 3/1/2014

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: http://www.karger.com/NIM

Abstract

Objective: Recombinant human interferon (rhIFN)-α is a potent immunoregulator having a wide range of therapeutic applications. In the present study, rhIFN-α was evaluated for its neuroimmunomodulatory activity. Method: Dose-dependent gene expression of cytokines and chemokines in the brain of rhIFN-administered mice was studied using real-time SYBR green PCR. Results: Statistically significant increase in expression levels of tumor necrosis factor-α, interleukin (IL)-6, IL-1β and IFN-γ were observed. Conclusion: The findings indicate that rhIFN-α may be used at an optimized dose to cause appropriate neuromodulation of cytokine/chemokine secretion that can aid in the development of therapeutic approaches for many infectious diseases of the central nervous system for which therapies are lacking.


  

Author Contacts

Sandeepan Mukherjee
Department of Virology & Immunology
Haffkine Institute
Parel, Mumbai 400012 (India)
E-Mail sandeepanm@gmail.com

  

Article Information

Received: October 3, 2013
Accepted after revision: November 15, 2013
Published online: March 1, 2014
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 2, Number of References : 46

  

Publication Details

Neuroimmunomodulation

Vol. 21, No. 5, Year 2014 (Cover Date: June 2014)

Journal Editor: Savino W. (Rio de Janeiro)
ISSN: 1021-7401 (Print), eISSN: 1423-0216 (Online)

For additional information: http://www.karger.com/NIM


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 10/3/2013 10:04:04 AM
Accepted: 11/15/2013
Published online: 3/1/2014

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: http://www.karger.com/NIM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.